A new paradigm for accelerating evaluation of investigational therapies during public health emergencies caused by emerging infectious diseases could permit therapies shown to be safe and effective to reach patients as soon as possible.
No takes yet. Share an insight, caveat, or question.
Borio et al. (2015) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: